


Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

LSP\ac

NY\_MAIN 230126 v1

2011.01.10 10:06:15

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

8. (Amended) A pharmaceutical composition comprising at least one staurosporin derivative or pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5 and a pharmaceutically acceptable carrier.

12. (Amended) An enhancer for activity of an antitumor agent, comprising the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5, as an active ingredient.

14. (Amended) An agent for abrogating accumulation action at the G2 or S stage of the cell cycle, comprising the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5, as an active ingredient.

15. (Amended) An antitumor agent comprising at least one staurosporin derivative or pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5.

16. (Amended) A pharmaceutical composition comprising at least one staurosporin derivative or pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5.

23. (Amended) A method for treating a malignant tumor, comprising the step of administering a therapeutically effective amount of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5.

24. (Amended) A method for enhancing the activity of an antitumor agent, comprising the step of administering a therapeutically effective amount of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5.

25. (Amended) A method for abrogating accumulation action at the G2 or S stage of the cell cycle, comprising the step of administering a therapeutically effective amount of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5.

26. (Amended) Use of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5 for the manufacture of an antitumor agent.

27. (Amended) Use of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5 for the manufacture of an enhancer for activity of an antitumor agent.

28. (Amended) Use of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to [7] 5 for production of an agent for abrogating accumulation action at the G2 or S stage of the cell cycle.